在线客服: 点击这里给我发消息  新用户使用步骤:会员注册→充值→重新登入→进入资源
标题:Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
时间:2020-05-21 15:47:46
DOI:10.1007/s00280-020-04030-2
PMID:32055930
大小:1379 kb
页数:12 PAGES
下载: 点击下载
预览:

浏览器不支持嵌入PDF阅读,打开新页面在线阅读

目录:
  • Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
    • Abstract
      • Objective
      • Methods
      • Results
      • Conclusions
    • Introduction
    • Materials and methods
      • Study design
      • Patient selection
      • Compliance and ethical standards
      • Assessments
      • Plasma pharmacokinetic sampling and assay
    • Results
      • Patient characteristics
      • RP2D determination
      • Adverse events
      • Response assessment and follow-up
      • Pharmacokinetics results
    • Discussion
    • References

本页内容由网络收集而来,版权归原创者所有,如有侵权请及时联系